Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 3/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 6/20 | 0.35 |
| ▸ | TYK2 | P29597 | 6/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690564 | 0.85 | PTK2 (0.61) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL691670 | 0.80 | PTK2 (0.79) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL691964 | 0.78 | MAPK1 (0.63) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL22174998 | 0.78 | PTK2 (0.62) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL692860 | 0.75 | PTK2 (0.59) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL690133 | 0.75 | MAPK1 (0.55) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL1293127 | 0.75 | PTK2 (0.77) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL1293051 | 0.75 | PTK2 (0.50) | PTK2MAPK1RPS6KA1MAPK3JAK1 | |
| SCHEMBL1559144 | 0.73 | MAPK3 (0.66) | PTK2MAPK1MAPK3 | |
| SCHEMBL690300 | 0.71 | PTK2 (0.75) | PTK2MAPK1MAPK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113475-A1 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK | PTK2, PAK1, CTTN | PTK2 1/4885MAPK1 221/4885RPS6KA1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.